Article
Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jul 2026
Uppal Manik, Bhinder Bhavneet, Marderstein Andrew R, Lee Batlevi Connie, Falchi Lorenzo, Hamlin Paul, Horwitz Steven, Kumar Anita, Noy Ariela, Zelenetz Andrew D, Lue Jennifer K, Torka Pallawi, Epstein-Peterson Zachary D, Arcila Maria, Dogan Ahmet, Imber Brandon, Yahalom Joachim, Vardhana Santosha A, Intlekofer Andrew, Raj Sandeep, Shouval Roni, Hodkinson Brendan, Stokes Matthew E, Kittai Adam S, Brody Joshua D, Elemento Olivier, Salles Gilles, Joffe Erel
Abstract excerpt
PURPOSE: Mutations in TP53, detected in over 20% of diffuse large B-cell lymphomas (DLBCLs), are associated with poor prognosis. However, clinical outcomes among patients with TP53-mutant disease vary, with some patients showing treatment responses similar to those with wild-type TP53. This study aims to understand the clinical and molecular determinants underlying poor outcomes in TP53-mutant DLBCL. METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
